Comment on “Serum human epididymis protein 4 is associated with the treatment response of concurrent chemo-radiotherapy and prognosis in patients with locally advanced non-small cell lung cancer” by Lan WG et al.

被引：0
|
作者：
G. Yavas
C. Yavas
S. Akyurek
机构：
[1] Selcuk University,Department of Radiation Oncology
[2] Ankara University,Department of Radiation Oncology
来源：
Clinical and Translational Oncology | 2018年 / 20卷
关键词：
Serum HE4; Human Epididymis Protein 4 (HE4); Concurrent Chemoradiotherapy; Shorter RFS; Smoking Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：801 / 802
页数：1
相关论文
共 50 条
  • [31] PROGNOSIS OF DYNAMIC MR IMAGING AND DIFFUSION WEIGHTED IMAGING FOR STAGE III NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMO-RADIOTHERAPY
    Li, Baosheng
    Wang, Yinxia
    Chen, Zhaoqiu
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 158 - 158
  • [32] Stereotactic ablative radiotherapy and durvalumab: The backbone of unresectable locally advanced non-small cell lung cancer patients unfit to concurrent chemo-radiotherapy - Rib of START-NEW-ERA trial
    Arcidiacono, F.
    Trippa, F.
    Maranzano, E.
    Italiani, M.
    Casale, M.
    Anselmo, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S112 - S112
  • [33] Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer
    Olszyna-Serementa, Marta
    Zaborowska-Szmit, Magdalena
    Szmit, Sebastian
    Jaskiewicz, Piotr
    Zajda, Katarzyna
    Krzakowski, Maciej
    Kowalski, Dariusz M. M.
    CURRENT ONCOLOGY, 2023, 30 (02) : 2049 - 2060
  • [34] Concomitant chemo-radiotherapy following induction chemotherapy with paclitaxel-gemcitabine in patients with inoperable locally advanced non-small cell lung cancer (NSCLC)
    Kosmidis, P
    Fountzilas, G
    Samantas, E
    Dimopoulos, A
    Goga, H
    Skarlos, D
    Pspacostas, P
    Boukovinas, J
    Bakogiannis, C
    Nicolaides, C
    LUNG CANCER, 2005, 49 : S254 - S254
  • [35] SERIAL 4DPET/4DCT IMAGING TO PREDICT LONG-TERM RESPONSE AFTER CHEMO-RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
    Tong, Daniel
    Sun, Alex
    Bezjak, Andrea
    Yap, Mei Ling
    Ye, Xiang Y.
    Bissonnette, Jean-Pierre
    RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S58 - S59
  • [36] Immunohistochemistry for phosphorylated EGF receptor predicts survival and phosphorylated ERK predicts tumor response to chemo-radiotherapy in unresectable, locally advanced non-small cell lung cancer patients
    Cutz, J-C
    Tsakaridis, T. S.
    Wright, J.
    Hirte, H.
    Singh, G.
    Tsao, M-S
    LABORATORY INVESTIGATION, 2008, 88 : 339A - 339A
  • [37] Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer
    Rabatic, Bryan M.
    Kong, Feng-Ming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (02) : 190 - 194
  • [38] Cons: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with inoperable large volume stage III non-small cell lung cancer
    Rodrigues, George
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (02) : 195 - 197
  • [39] Preoperative concurrent chemo-radiotherapy (CT-RT) in non-small cell lung cancer patients with superior sulcus tumor (SST)
    Favaretto, Adolfo G.
    Loreggian, Lucio
    Rea, Federico
    Marchi, Rita
    Stefani, Micaela
    Bortolotti, Luigi
    Aversa, Savina
    Friso, Maria L.
    Monfardini, Silvio
    ANNALS OF ONCOLOGY, 2004, 15 : 171 - 172
  • [40] Circulating Growth Differentiation Factor 15 as a Biomarker in Patients with Unresected Locally Advanced Non-Small Cell Lung Cancer Treated with Chemo-Radiotherapy with or without Metformin
    DiPastena, F.
    Pond, G.
    Ahmadi, E.
    Tsakiridis, E. E.
    Steinberg, G. R.
    Tsakiridis, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E14 - E15
12345